Zongjie Gan
Chongqing, 400016, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence.
Journal: Journal of medicinal chemistry
Published: March 10, 2026
Novel Gemini surfactant-polyglutamic acid composite system enhances DNA delivery via a "Dual-Engine" uptake strategy.
Journal: International journal of pharmaceutics
Published: February 04, 2026
Dual AMPK activation and TXNIP suppression underlie the superior anti-diabetic action of rosiglitazone-metformin co-crystal (RZM): evidence from preclinical models.
Journal: Journal of drug targeting
Published: July 14, 2025
A dual-peptides and specific promoter-modified nano gene delivery system for myocardial hypertrophy treatment.
Journal: International journal of biological macromolecules
Published: December 12, 2024
Design, synthesis, and biological evaluation of Ponatinib-based N-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors.
Journal: European journal of medicinal chemistry
Published: November 06, 2024
Construction and evaluation of liposomal drug delivery system for an ALK/HDACs dual-targeted inhibitor with sustained release and enhanced antitumor effect.
Journal: Drug delivery and translational research
Published: June 03, 2024
Design, synthesis, and biological evaluation of naphthalene imidazo[1,2-b]pyridazine hybrid derivatives as VEGFR selective inhibitors.
Journal: Archiv der Pharmazie
Published: May 24, 2024
Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 19, 2023
N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer.
N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer.
Journal: European journal of pharmacology
Published: February 10, 2023
Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: September 13, 2022
T-17, a novel cyclin-dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis.
Journal: Drug development research
Published: May 18, 2022
The Biological Fate of a Novel Anticancer Drug Candidate TNBG-5602: Metabolic Profile, Interaction with CYP450, and Pharmacokinetics in Rats.
Journal: Molecules (Basel, Switzerland)
Published: March 21, 2022
Last Updated: 09/26/2026